Factors associated with increased prevalence of human papillomavirus infection in a cohort of HIV-infected Brazilian women

International Journal of Infectious Diseases

Volumn 13, Issue 1, 2009, Pages 72-80

  Grinsztejn, Beatriz ^a   Veloso, Valdilea Gonçalves ^a   Levi, José Eduardo ^b   Velasque, Luciane ^a   Luz, Paula Mendes ^a   Friedman, Ruth Khalili ^a   Andrade, Angela Cristina ^a   Moreira, Ronaldo Ismerio ^a   Russomano, Fabio ^c   Pilotto, José Henrique ^a   Bastos, Francisco Inacio ^d   Palefsky, Joel ^e  

^a Funda??o Oswaldo Cruz   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d Brazil   (Brazil)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brazil; Evandro Chagas Research Institute cohort; Human immunodeficiency virus; Human papillomavirus; Prevalence ratio

Indexed keywords

ADULT; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; CONDOM; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; RISK ASSESSMENT; SELF REPORT; SEXUAL INTERCOURSE; VIRUS INFECTION; WART VIRUS;

EID: 57849161885     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2008.03.031     Document Type: Article

References (49)

1. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
2. Massad L.S., Riester K.A., Anastos K.M., Fruchter R.G., Palefsky J.M., Burk R.D., et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. J Acquir Immune Defic Syndr 21 (1999) 33-41
3. Palefsky J.M., and Holly E.A. Chapter 6: Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr 31 (2003) 41-46
4. Wright T.C., Ellerbrock T.V., Chiasson M.A., Vandevanter N., Sun X.W., Brudney K., et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus-prevalence, risk-factors, and validity of Papanicolaou smears. Obstet Gynecol 84 (1994) 591-597
5. Palefsky J.M. Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 15 (2003) 382-388
6. Minkoff H., Feldman J., DeHovitz J., Landesman S., and Burk R. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 178 (1998) 982-986
7. Vernon S.D., Reeves W.C., Clancy K.A., Laga M., Stlouis M., Gary H.E., et al. A longitudinal study of human papillomavirus DNA detection in human immunodeficiency virus type-1-seropositive and type-1-seronegative women. J Infect Dis 169 (1994) 1108-1112
8. Orem J., Otieno M.W., and Remick S.C. AIDS-associated cancer in developing nations. Curr Opin Oncol 16 (2004) 468-476
9. INCA. Estimates 2006: cancer incidence in Brazil (2006), Ministry of Health, National Institute of Cancer, Brazil p. 96
10. Campos D.P., Ribeiro S.R., Grinsztejn B., Veloso V.G., Valente J.G., Bastos F.I., et al. Survival of AIDS patients using two case definitions, Rio de Janeiro, Brazil, 1986-2003. AIDS 19 Suppl 4 (2005) S22-S26
11. Bower M., Palmieri C., and Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 19 (2006) 14-19
12. Clifford G.M., Polesel J., Rickenbach M., Dal Maso L., Keiser O., Kofler A., et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97 (2005) 425-432
13. Grinsztejn B., Bastos F.I., Veloso V.G., Friedman R.K., Pilotto J.H., Schechter M., et al. Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. Int J STD AIDS 17 (2006) 473-478
14. Barros A.J., and Hirakata V.N. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 3 (2003) 21
15. Cantoni E. Analysis of robust quasi-deviances for generalized linear models. J Stat Software 10 (2004) 1-9
16. Skov T., Deddens J., Petersen M.R., and Endahl L. Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol 27 (1998) 91-95
17. Goedert J.J., Cote T.R., Virgo P., Scoppa S.M., Kingma D.W., Gail M.H., et al. Spectrum of AIDS-associated malignant disorders. Lancet 351 (1998) 1833-1839
18. Maiman M., Fruchter R.G., Serur E., Remy J.C., Feuer G., and Boyce J. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 38 (1990) 377-382
19. Serwadda D., Wawer M.J., Shah K.V., Sewankambo N.K., Daniel R., Li C., et al. Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus. J Infect Dis 180 (1999) 1316-1319
20. Sirera G., Videla S.N., Castella E., Cavalle L., Grane N., Llatjos M., et al. Contribution of human papillomavirus second-generation hybrid capture test for the diagnosis of cervical pathology in HIV-infected outpatients. Med Clin (Barc) 125 (2005) 127-131
21. Levi J.E., Kleter B., Quint W.G., Fink M.C., Canto C.L., Matsubara R., et al. High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J Clin Microbiol 40 (2002) 3341-3345
22. Ellerbrock T.V., Chiasson M.A., Bush T.J., Sun X.W., Sawo D., Brudney K., et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 283 (2000) 1031-1037
23. Goncalves M.A., Massad E., Burattini M.N., and Villa L.L. Relationship between human papillomavirus (HPV) genotyping and genital neoplasia in HIV-positive patients of Santos City, Sao Paulo, Brazil. Int J STD AIDS 10 (1999) 803-807
24. Levi J.E., Fernandes S., Tateno A.F., Motta E., Lima L.P., Eluf-Neto J., et al. Presence of multiple human papillomavirus types in cervical samples from HIV-infected women. Gynecol Oncol 92 (2004) 225-231
25. Palefsky J.M., Minkoff H., Kalish L.A., Levine A., Sacks H.S., Garcia P., et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 91 (1999) 226-236
26. Miotti P.G., Dallabetta G.A., Daniel R.W., Canner J.K., Chiphangwi J.D., Liomba G.N., et al. Cervical abnormalities, human papillomavirus, and human immunodeficiency virus infections in women in Malawi. J Infect Dis 173 (1996) 714-717
27. Shah K.V., Solomon L., Daniel R., Cohn S., and Vlahov D. Comparison of PCR and hybrid capture methods for detection of human papillomavirus in injection drug-using women at high risk of human immunodeficiency virus infection. J Clin Microbiol 35 (1997) 517-519
28. Franco E.L., Villa L.L., Sobrinho J.P., Prado J.M., Rousseau M.C., Desy M., et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180 (1999) 1415-1423
29. Heard I., Tassie J.M., Schmitz V., Mandelbrot L., Kazatchkine M.D., and Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load. Obstet Gynecol 96 (2000) 403-409
30. Rezza G., Giuliani M., Serraino D., Branca M., Benedetto A., Garbuglia A., et al. Risk factors for cervical presence of human papillomavirus DNA among women at risk for HIV infection. DIANAIDS Collaborative Study Group. Epidemiol Infect 121 (1998) 173-177
31. Sun X.W., Kuhn L., Ellerbrock T.V., Chiasson M.A., Bush T.J., and Wright Jr. T.C. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 337 (1997) 1343-1349
32. Dolei A., Curreli S., Marongiu P., Pierangeli A., Gomes E., Bucci M., et al. Human immunodeficiency virus infection in vitro activates naturally integrated human papillomavirus type 18 and induces synthesis of the L1 capsid protein. J Gen Virol 80 (1999) 2937-2944
33. Burk R.D., Ho G.Y., Beardsley L., Lempa M., Peters M., and Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 174 (1996) 679-689
34. Munoz N., Kato I., Bosch F.X., Eluf-Neto J., De Sanjose S., Ascunce N., et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 23 (1996) 504-510
35. Trottier H., and Franco E.L. The epidemiology of genital human papillomavirus infection. Vaccine 24 Suppl 1 (2006) S1-15
36. Manhart L.E., Holmes K.K., Koutsky L.A., Wood T.R., Kenney D.L., Feng Q., et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis 33 (2006) 502-508
37. Reeves W.C., Gary Jr. H.E., Johnson P.R., Icenogle J.P., Brenes M.M., de Britton R.M., et al. Risk factors for genital papillomavirus infection in populations at high and low risk for cervical cancer. J Infect Dis 170 (1994) 753-758
38. Strickler H.D., Burk R.D., Fazzari M., Anastos K., Minkoff H., Massad L.S., et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 97 (2005) 577-586
39. Goncalves M.A., Burattini M.N., Donadi E.A., and Massad E. Risk factors associated with genital warts in HIV-positive Brazilian women. Tumori 89 (2003) 9-15
40. Manhart L.E., and Koutsky L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 29 (2002) 725-735
41. Stone K.M., Timyan J., and Thomas E.L. Barrier methods for the prevention of sexually transmitted diseases. In: Holmes K.K., Mardh P., and Sparling P.F. (Eds). Sexually transmitted diseases. 3rd ed. (1999), McGraw-Hill, New York 1307-1321
42. Winer R.L., Hughes J.P., Feng Q., O'Reilly S., Kiviat N.B., Holmes K.K., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354 (2007) 2645-2654
43. Kjaer S.K., van den Brule A.J., Bock J.E., Poll P.A., Engholm G., Sherman M.E., et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types?. Cancer Epidemiol Biomarkers Prev 6 (1997) 799-805
44. Richardson H., Franco E., Pintos J., Bergeron J., Arella M., and Tellier P. Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. Sex Transm Dis 27 (2000) 79-86
45. Brown D, FUTURE study group. HPV type 6/11/16/18 vaccine: first analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. 24th International Papillomavirus Conference and Clinical Workshop. Beijing International Convention Center, 2007.
46. Clifford G.M., Goncalves M.A., and Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 20 (2006) 2337-2344
47. de Sanjose S., Diaz M., Castellsague X., Clifford G., Bruni L., Munoz N., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7 (2007) 453-459
48. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 (2007) 621-632
49. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27